1.The Preliminary Study of Our Country's Medical Treatment Signs System——With the surgical operation sign system for angle of view
Chinese Medical Ethics 1995;0(04):-
The social public signs system to exist mistake area on the understanding to the our country current medical treatment,the hospital usually uses this as to don't need the reason of responsibility,but sufferer then"life and death form" that it sees to sign as the compelled by circumstances,this makes to cure to suffer from an antinomy more for turn worse.Right know a medical treatment a signing system for alleviate to cure to suffer from an antinomy,set up diapason to cure to suffer from a relation to have great significance.
2.Money Management Skills Training for Children with Intellectual Disabilities in Other Countries (review)
Chinese Journal of Rehabilitation Theory and Practice 2015;21(2):176-179
Many special educators have focused on money management skills as an important educational outcome for children with intellectual disabilities for transition to adult living. Existing Western resources analyzed the money computation skill and purchasing skill for children with intellectual disabilities, and described aids and instructional strategies to teach money management skills for individual with intellectual disabilities. Future studies may be focused on early education, objects targeted, developing more aids, for more money management skills, and investigating instructional strategies.
3.Biological characteristics of IL-24 and mechanisms of its anti-tumor action
Journal of International Oncology 2010;37(9):657-661
Studies have shown that IL-24 is the only cytokine capable of inhibiting tumor growth and neovascularization as well as stimulating immune system. IL-24 exerts its inhibition effects through pathways independent of p53, Rb, p16 and other tumor suppressor genes and has no effect on normal cells. IL-24 has emerged as a hot topic in cancer therapy research.
4.Recent Progression in the clinical application of Permanent cardiac pacemakers
Chinese Journal of Tissue Engineering Research 2007;11(40):8213-8216
OBJECTIVE:TO summarize the newest clinical application of permanent cardiac pacemaker, and introduce the relationship between the therapy efficacy and mechanism.DATA SOURCES: Related papers were searched in Pubmed from January 2000 to December 2006 with the terms of "pacemaker,application",and the language of paper was limited to English,at the same time,related papers were searched in WangFang Database with the same terms and the language of paper was limited to Chinese.STUDY SELECTION:The papers relevant to the newest large-scale clinical trial about the cardiac pacemaker were primarily collected.Exclusion criteria:repetitive studies.DATA EXTRACTION:A total of 203 pieces of papers related to the newest clinical application of cardiac pacemaker were collected,among which,30 pieces accorded with the inclusion criteria.DATA SYNTHESIS:The pacemaker can simulate the normal myocardium cell's function pacing and conducting the rhythm. Consequently it can substitute the abnormal myocardium cell to ensure the sequence and completeness of the cardiac pacing and conducting system,the natural electrophysiological activity,and the efficiency of the cardiac ejection and blood supply.The clinical application is not only for single bradycardia, but also for cardiac electric failure, cardiac electric turbulence,and some heart diseases without cardiac electric abnormity.With pacemaker miniaturization,digital signal processing, improved diagnostics and endocardial electrograms, modern pacemakers are able to offer a sophisticated therapeutic and diagnostic platform for the patients with refractory symptoms.CONCLUSION:The pacemaker can simulate the normal myocardium cell's function pacing and conducting the rhythm.It therapy for congenital heart disease.
5.Recent advances of molecular genetic characteristics of small cell lung cancer
China Oncology 2014;(8):630-635
Small cell lung cancer (SCLC) is an aggressive malignancy with fairly poor prognosis. Innovative treatment based on improved understanding of the genetic alterations of SCLC is awaited. Recently, a number of potential targets or important oncogenic pathways have been identified by the next generation sequencing or other systematic genomic analysis in SCLC. In this review, we summarised the new ifndings of genetic characteristics in SCLC.
6.Effects of strengthened atorvastatin treatment on Hcy and NT-proBNP in patients with non-ST-segment ele-vation acute coronary syndrome
Chinese Journal of Primary Medicine and Pharmacy 2014;(24):3759-3761
Objective To study effects of strengthened atorvastatin treatment on homocysteine( Hcy) and N-terminal B-type natriuretic peptide( NT-proBNP) in patients with non-ST-segment elevation acute coronary syndrome. Methods 120 patients with non-ST-segment elevation acute coronary syndrome were randomly divided into the two groups,the observation group(n=60 cases) and the control group(n=60 cases).The patients in the observation group were treated through the basis of conventional therapy plus atorvastatin 40mg/night treatment,while the patients in the control group were treated through the basis of conventional therapy plus atorvastatin 20mg/night treatment. They were all treated for two months.Plasma Hcy and NT-proBNP were detected before and after treatment.Results Hcy in the observation group and the control group before treatment were ( 25.5 ±8.6 )μmol/L and ( 26.3 ± 9.1)μmol/L,respectively,(10.3 ±4.7)μmol/L and (16.9 ±7.1)μmol/L after treatment.NT-proBNP in the obser-vation group and the control group before treatment were (374.7 ±39.2)ng/L and (359.6 ±36.1)ng/L,respective-ly,(127.4 ±15.3)ng/L and (237.1 ±24.3)ng/L after treatment.After treatment,plasma Hcy and NT-proBNP were significantly reduced than those before treatment and after treatment(P<0.05).During follow-up,the two groups showed no elevated liver enzymes and muscle enzymes and lead to withdrawal from happening.Conclusion Strength-ened atorvastatin treatment can significantly reduce Hcy and NT-proBNP in patients with non-ST-segment elevation acute coronary syndrome.
7.The influence of fasudil on plasma H2 S and NT-proBNP in patients with chronic pulmonary heart disease
Chinese Journal of Primary Medicine and Pharmacy 2014;(21):3284-3286
Objective To explore the influence of fasudil on plasma hydrogen sulfide(H2S)and N-terminal B-type natriuretic peptide( NT-proBNP) in patients with chronic pulmonary heart disease.Methods According to the digital table,102 patients with chronic pulmonary heart disease were randomly divided into the observation group and the control group, each group in 51 cases.The patients in the control group were treated through the conventional treatment,while the patients in the observation group were treated through the conventional treatment plus fasudil. They were treated for 14 days.The mean pulmonary artery pressure( MPAP) ,plasma H2 S and NT-proBNP were detec-ted.Results After treatment,the total effective rate in the observation group was 96.1%,which was higher than 86.3%in the control group(χ2 =4.046,P<0.05).MPAP in the two groups of patients were significantly decreased, and the observation group decreased more significantly than the control group(t=7.246,P<0.05).After treatment, plasma H2S were significantly higher,and the observation group increased more significantly(t=2.856,P<0.05), plasma NT-proBNP in two groups after treatment were significantly reduced,and the observation group decreased sig-nificantly(t=10.706,P<0.05).Conclusion Fasudil can be significantly improved plasma H2S and NT-proBNP in patients with chronic pulmonary heart disease.
8.To elaborate the pathogenesis and clinical intervention of metabolic syndrome
Chinese Journal of Endocrinology and Metabolism 2015;31(3):199-200
The metabolic syndrome (MS) is one of the major risk factors for cardiovascular disease.The pathogenesis of MS is not fully understood.In addition to insulin resistance and central obesity,some other factors such as resting heart rate are also thought to play certain roles.The primary strategy of the intervention is still relying on lifestyle modification including healthy dietary habits.
9.SARS-like virus in the Middle East: a truly bat-related coronavirus causing human diseases.
Protein & Cell 2012;3(11):803-805
Animals
;
Chiroptera
;
virology
;
Coronavirus
;
classification
;
genetics
;
isolation & purification
;
Coronavirus Infections
;
transmission
;
virology
;
Databases, Genetic
;
Genome, Viral
;
Humans
;
Male
;
Middle Aged
;
Middle East
;
Phylogeny
;
SARS Virus
;
classification
;
genetics
;
isolation & purification
;
Severe Acute Respiratory Syndrome
;
virology
10.Effect of dopamine receptor agonist apomorphine on scopolamine induced memory deficits in mice.
Hui-Di YANG ; Zheng YANG ; Tao-Di LIU
Chinese Journal of Applied Physiology 2014;30(3):259-263
OBJECTIVETo research the mechanism of dopamine (DA) controlled memory in mice.
METHODSMice received i.p. injection of scopolamine (0.3 mg/kg, SCOP 0.3, and 3.0mg/kg, SCOP 3.0, respectively, n = 10) and saline (NS, n = 10) for 60 days in experiment 1. Memory of mice was detected by dark avoidance behavior in the 53" d and the 60"' d. Animals were sacrificed after the memory test; brain tissues were processed for Fos-ir and TH-ir by immunohistochemistry. Mice were divided into four groups according results of expri-ment 1, they received i.p. injection of apomorphine (0.1 mg/kg, APO 0.1, 0.5 mg/kg, APO 0.5, and 2.0 mg/kg, APO2.0 respectively, n = 10).
RESULTSMemory was inhibited in mice injected scopolamine 3.0 mg/kg. Latency was significantly less than in NS group, only 1/ 4 that of NS group (P > 0.05). The number of mistake of SCOP 3.0 group increased about four times than that of NS group (P > 0.05). But there was no difference of latency and number of mistake between SCOP 0.3 and NS group in expriment 1. Scopolamine-induced memory deficit was associated with decreased cellular activation, indicated by Fos immunoreactive (ir) staining, in NAcc CA1 and CA3 (P < 0.05), and also associated with decreases in the number of cells labeled for tyrosine hydroxylase (TH-ir), the rate limiting enzyme for dopamine conversion (P < 0.01) and the number of cells co-labeled for TH-ir/Fos-ir (P <0.01) in the ventral tegmental area(VTA), apomorphine lessened scopolamine-induced memory deficit in experiment 2. The number of cells co-labeled for TH-ir/Fos-ir (P <, 0.05) was increased in VTA after apomorphine treatment.
CONCLUSIONApomorphine lessened scopolamine-induced memory deficit in mice by increasing DA activities in VTA.
Animals ; Apomorphine ; pharmacology ; Disease Models, Animal ; Dopamine Agonists ; pharmacology ; Male ; Memory Disorders ; chemically induced ; drug therapy ; Mice ; Scopolamine Hydrobromide ; toxicity